Beat AML: promising results with enasidenib for AML in the frontline

Eytan Stein, MD, of the Memorial Sloan Kettering Cancer Center, New York City, NY, discusses the early results of the Beat AML Master Trial, evaluating the efficacy of the IDH2 inhibitor enasidenib, in previously untreated acute myeloid leukemia (AML) patients aged ≥60 years that have an IDH2 mutation. Speaking from the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA, Dr Stein summarizes the promising results and stresses the importance of the early management of complications such as differentiation syndrome.